Want to see GRI full AI Analyst Report?
GRI Stock Chart & Stats
$0.28
-$0.06(-7.48%)
At close: 4:00 PM EST
$0.28
-$0.06(-7.48%)
Day’s Range― - ―
52-Week Range$1.70 - $80.36
Previous CloseN/A
Volume96.89K
Average Volume (3M)96.15K
Market Cap
$3.15M
Enterprise Value-$10.78M
Total Cash (Recent Filing)$11.05M
Total Debt (Recent Filing)$58.00K
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Aug 19, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-241.87
Shares Outstanding1,770,838
10 Day Avg. Volume50,222
30 Day Avg. Volume96,151
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-3.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.39K
Enterprise Value/Ebitda0.77
Forecast
1Y Price Target
$21.00Price Target Upside7400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory MilestoneOrphan Drug designation provides up to seven years of US exclusivity, tax credits, fee waivers and closer FDA engagement. This materially improves development economics, raises partner interest odds, and enhances the commercial downside protection for GRI-0621 over the medium term.
Clinical DifferentiationPhase 2a data showing symptom improvement, favorable safety and biomarker evidence supports a mechanism-driven differentiation. That durability raises the probability of a successful pivotal program, strengthens IP filings and improves partnering and licensing leverage over the next 2–6 months.
Low Leverage / Improved EquityVery low financial leverage and materially improved equity reduce short-term solvency risk and preserve strategic optionality. Low debt limits fixed obligations, giving management flexibility to prioritize clinical milestones and partnership discussions before dilutive financing becomes necessary.
Bears Say
High Cash BurnSustained negative operating and free cash flow of roughly -$13.9M TTM means the company must rely on external funding to advance pivotal programs. Over months this raises dilution risk and can force hurried financings that compress strategic optionality if clinical timelines slip.
Weak ProfitabilityDeeply negative margins and a TTM net loss about $14M indicate the business cannot yet convert revenue into sustainable profits. Persistent unprofitability constrains reinvestment capacity and increases dependence on capital markets until a breakthrough clinical or commercial inflection occurs.
Revenue Volatility & Financing RelianceA small, volatile revenue base (including prior years with little or zero revenue) undermines self-funding of development. Coupled with heavy cash burn, this structural revenue instability makes long-term planning and trial funding contingent on successful asset de-risking or external capital/partners.
GRI Bio News
GRI FAQ
What was Gri Bio, Inc.’s price range in the past 12 months?
Gri Bio, Inc. lowest stock price was $1.70 and its highest was $80.36 in the past 12 months.
What is Gri Bio, Inc.’s market cap?
Gri Bio, Inc.’s market cap is $3.15M.
When is Gri Bio, Inc.’s upcoming earnings report date?
Gri Bio, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 39 days.
How were Gri Bio, Inc.’s earnings last quarter?
Gri Bio, Inc. released its earnings results on May 14, 2026. The company reported -$1.61 earnings per share for the quarter, missing the consensus estimate of -$1.605 by -$0.005.
Is Gri Bio, Inc. overvalued?
According to Wall Street analysts Gri Bio, Inc.’s price is currently Undervalued.
Does Gri Bio, Inc. pay dividends?
Gri Bio, Inc. does not currently pay dividends.
What is Gri Bio, Inc.’s EPS estimate?
Gri Bio, Inc.’s EPS estimate is -1.2.
How many shares outstanding does Gri Bio, Inc. have?
Gri Bio, Inc. has 1,770,838 shares outstanding.
What happened to Gri Bio, Inc.’s price movement after its last earnings report?
Gri Bio, Inc. reported an EPS of -$1.61 in its last earnings report, missing expectations of -$1.605. Following the earnings report the stock price went down -4.867%.
Which hedge fund is a major shareholder of Gri Bio, Inc.?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gri Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$21.00
▲(7400.00% Upside)
Technical Analysis
Ownership Overview
32.35%
Insiders
0.44% Mutual Funds
― Other Institutional Investors
66.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---